Form 8-K - Current report:
SEC Accession No. 0001437749-24-037243
Filing Date
2024-12-11
Accepted
2024-12-11 16:32:20
Documents
15
Period of Report
2024-12-09
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K krbp20241210_8k.htm   iXBRL 8-K 30339
2 EXHIBIT 10.1 ex_755832.htm EX-10.1 139291
  Complete submission text file 0001437749-24-037243.txt   339802

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA krbp-20241209.xsd EX-101.SCH 3410
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE krbp-20241209_def.xml EX-101.DEF 11820
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE krbp-20241209_lab.xml EX-101.LAB 15885
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE krbp-20241209_pre.xml EX-101.PRE 12035
17 EXTRACTED XBRL INSTANCE DOCUMENT krbp20241210_8k_htm.xml XML 2932
Mailing Address 7707 FANNIN ST. SUITE 140 HOUSTON TX 77054
Business Address 7707 FANNIN ST. SUITE 140 HOUSTON TX 77054 832-968-4888
Kiromic Biopharma, Inc. (Filer) CIK: 0001792581 (see all company filings)

EIN.: 464762913 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39619 | Film No.: 241541951
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)